Cargando…
Epac activation inhibits IL-6-induced cardiac myocyte dysfunction
Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signalin...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353818/ https://www.ncbi.nlm.nih.gov/pubmed/27995459 http://dx.doi.org/10.1007/s12576-016-0509-5 |
_version_ | 1783391034328219648 |
---|---|
author | Jin, Huiling Fujita, Takayuki Jin, Meihua Kurotani, Reiko Hidaka, Yuko Cai, Wenqian Suita, Kenji Prajapati, Rajesh Liang, Chen Ohnuki, Yoshiki Mototani, Yasumasa Umemura, Masanari Yokoyama, Utako Sato, Motohiko Okumura, Satoshi Ishikawa, Yoshihiro |
author_facet | Jin, Huiling Fujita, Takayuki Jin, Meihua Kurotani, Reiko Hidaka, Yuko Cai, Wenqian Suita, Kenji Prajapati, Rajesh Liang, Chen Ohnuki, Yoshiki Mototani, Yasumasa Umemura, Masanari Yokoyama, Utako Sato, Motohiko Okumura, Satoshi Ishikawa, Yoshihiro |
author_sort | Jin, Huiling |
collection | PubMed |
description | Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signaling has been traditionally understood to be cyclic AMP-dependent protein kinase (PKA)-mediated enforcement of cardiac contractility. We hypothesized that the exchange protein activated by cAMP (Epac), a newly identified target of cAMP signaling that functions independently of PKA, also plays a key role in this mechanism. In cultured cardiac myocytes, activation of Epac attenuated the inhibitory effect of interleukin-6 on the increase of intracellular Ca(2+) concentration and contractility in response to isoproterenol, most likely through inhibition of the Jak-STAT pathway via SOCS3, with subsequent changes in inducible nitric oxide synthase expression. These findings suggest a new role of catecholamine signaling in compensating for cardiac dysfunction in heart failure. Epac and its downstream pathway may be a novel target for treating cardiac dysfunction in endotoxemia. |
format | Online Article Text |
id | pubmed-6353818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-63538182019-02-21 Epac activation inhibits IL-6-induced cardiac myocyte dysfunction Jin, Huiling Fujita, Takayuki Jin, Meihua Kurotani, Reiko Hidaka, Yuko Cai, Wenqian Suita, Kenji Prajapati, Rajesh Liang, Chen Ohnuki, Yoshiki Mototani, Yasumasa Umemura, Masanari Yokoyama, Utako Sato, Motohiko Okumura, Satoshi Ishikawa, Yoshihiro J Physiol Sci Original Paper Pro-inflammatory cytokines are released in septic shock and impair cardiac function via the Jak-STAT pathway. It is well known that sympathetic and thus catecholamine signaling is activated thereafter to compensate for cardiac dysfunction. The mechanism of such compensation by catecholamine signaling has been traditionally understood to be cyclic AMP-dependent protein kinase (PKA)-mediated enforcement of cardiac contractility. We hypothesized that the exchange protein activated by cAMP (Epac), a newly identified target of cAMP signaling that functions independently of PKA, also plays a key role in this mechanism. In cultured cardiac myocytes, activation of Epac attenuated the inhibitory effect of interleukin-6 on the increase of intracellular Ca(2+) concentration and contractility in response to isoproterenol, most likely through inhibition of the Jak-STAT pathway via SOCS3, with subsequent changes in inducible nitric oxide synthase expression. These findings suggest a new role of catecholamine signaling in compensating for cardiac dysfunction in heart failure. Epac and its downstream pathway may be a novel target for treating cardiac dysfunction in endotoxemia. Springer Japan 2016-12-19 2018 /pmc/articles/PMC6353818/ /pubmed/27995459 http://dx.doi.org/10.1007/s12576-016-0509-5 Text en © The Author(s) 2016, corrected publication 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
spellingShingle | Original Paper Jin, Huiling Fujita, Takayuki Jin, Meihua Kurotani, Reiko Hidaka, Yuko Cai, Wenqian Suita, Kenji Prajapati, Rajesh Liang, Chen Ohnuki, Yoshiki Mototani, Yasumasa Umemura, Masanari Yokoyama, Utako Sato, Motohiko Okumura, Satoshi Ishikawa, Yoshihiro Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title | Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title_full | Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title_fullStr | Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title_full_unstemmed | Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title_short | Epac activation inhibits IL-6-induced cardiac myocyte dysfunction |
title_sort | epac activation inhibits il-6-induced cardiac myocyte dysfunction |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353818/ https://www.ncbi.nlm.nih.gov/pubmed/27995459 http://dx.doi.org/10.1007/s12576-016-0509-5 |
work_keys_str_mv | AT jinhuiling epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT fujitatakayuki epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT jinmeihua epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT kurotanireiko epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT hidakayuko epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT caiwenqian epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT suitakenji epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT prajapatirajesh epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT liangchen epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT ohnukiyoshiki epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT mototaniyasumasa epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT umemuramasanari epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT yokoyamautako epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT satomotohiko epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT okumurasatoshi epacactivationinhibitsil6inducedcardiacmyocytedysfunction AT ishikawayoshihiro epacactivationinhibitsil6inducedcardiacmyocytedysfunction |